【文章內(nèi)容簡介】 .............................................................90角膜病毒感染 ....................................................................................................................................90棘阿米巴角膜炎 ................................................................................................................................913 / 43蠶食性角膜潰瘍 ................................................................................................................................92干眼 ....................................................................................................................................................93（二）急性淺層鞏膜炎和鞏膜炎 ........................................................................................................93淺層鞏膜炎 ........................................................................................................................................93鞏膜炎 ................................................................................................................................................94（三）葡萄膜炎 ....................................................................................................................................95（四）視網(wǎng)膜疾病 ................................................................................................................................97白塞綜合征 ........................................................................................................................................97Vogt小柳原田病 ...............................................................................................................................98視網(wǎng)膜血管炎 ....................................................................................................................................99（五）視神經(jīng)炎 ..................................................................................................................................101（六）外傷性視神經(jīng)病變 ..................................................................................................................101（七）眼科手術(shù)后 ..............................................................................................................................102角膜移植術(shù)后 ..................................................................................................................................102青光眼術(shù)后 ......................................................................................................................................104白內(nèi)障術(shù)后 ......................................................................................................................................105視網(wǎng)膜扣帶術(shù)后 ..............................................................................................................................106玻璃體手術(shù)后 ..................................................................................................................................106十、皮膚疾病 ..........................................................................................................................................107（一）天皰瘡 ......................................................................................................................................107（二）大皰性類天皰瘡 ......................................................................................................................108（三）藥物性皮炎 ..............................................................................................................................109（四）紅皮病 ......................................................................................................................................111（五）濕疹與皮炎 ..............................................................................................................................111（六）銀屑病 ......................................................................................................................................112十一、重癥患者的加強(qiáng)醫(yī)療 ..................................................................................................................114（一）休克 ..........................................................................................................................................114感染性休克 ......................................................................................................................................114過敏性休克 ......................................................................................................................................115創(chuàng)傷性休克 ......................................................................................................................................116（二）急性肺損傷和（或）ARDS ......................................................................................................117（三）急性腦水腫 ..............................................................................................................................118十二、器官移植排斥反應(yīng) ......................................................................................................................119（一）腎臟移植排斥反應(yīng) ..................................................................................................................119（二）肝臟移植排斥反應(yīng) ..................................................................................................................122十三、骨科疾病 ......................................................................................................................................123（一）運(yùn)動(dòng)系統(tǒng)慢性損傷 ..................................................................................................................123（二）急性脊髓損傷 ..........................................................................................................................1244 / 43前 言糖皮質(zhì)激素類藥物（以下簡稱糖皮質(zhì)激素）在臨床各科多種疾病的診斷和治療上廣泛應(yīng)用。但臨床不合理應(yīng)用非常突出，給患者的健康乃至生命造成重大影響。為規(guī)范糖皮質(zhì)激素的臨床應(yīng)用，避免或減少不良反應(yīng)，保障患者的用 藥安全，提高 療效及降低醫(yī)藥費(fèi) 用，特制定《糖皮質(zhì)激素類藥物臨床應(yīng)用指導(dǎo)原則》（以下簡稱《指導(dǎo)原則》）。在臨床診療工作中應(yīng)參考和遵循本《指導(dǎo)原則》，說明如下：《指導(dǎo)原則》為臨床應(yīng)用糖皮質(zhì)激素獲取最佳療效并最大程度避免或減少不良反應(yīng)而制定。臨床醫(yī)師應(yīng)結(jié)合患者具體情況，制定個(gè)體化給藥方案?！吨笇?dǎo)原則》僅涉及臨床常用的糖皮質(zhì)激素，重點(diǎn)介 紹 各類